恒瑞医药(600276.SH)：HRS-6093片获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of HRS-6093 tablets, a novel and efficient oral KRASG12D inhibitor that specifically targets the KRASG12D mutation protein to exert anti-tumor effects [1] Company Summary - The company is set to initiate clinical trials for HRS-6093 tablets in the near future following regulatory approval [1] - HRS-6093 is characterized as a new, selective oral medication aimed at treating tumors associated with the KRASG12D mutation [1]